| KRAS: the critical driver and therapeutic target for pancreatic cancer AM Waters, CJ Der Cold Spring Harbor perspectives in medicine 8 (9), a031435, 2018 | 776 | 2018 |
| Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer KL Bryant, CA Stalnecker, D Zeitouni, JE Klomp, S Peng, AP Tikunov, ... Nature medicine 25 (4), 628-640, 2019 | 578 | 2019 |
| Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer GA Hobbs, NM Baker, AM Miermont, RD Thurman, M Pierobon, TH Tran, ... Cancer discovery 10 (1), 104-123, 2020 | 161 | 2020 |
| Differential effector engagement by oncogenic KRAS TL Yuan, A Amzallag, R Bagni, M Yi, S Afghani, W Burgan, N Fer, ... Cell reports 22 (7), 1889-1902, 2018 | 120 | 2018 |
| Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers I Ozkan-Dagliyan, JN Diehl, SD George, A Schaefer, B Papke, ... Cell reports 31 (11), 2020 | 79 | 2020 |
| Evaluation of the selectivity and sensitivity of isoform-and mutation-specific RAS antibodies AM Waters, I Ozkan-Dagliyan, AV Vaseva, N Fer, LA Strathern, GA Hobbs, ... Science signaling 10 (498), eaao3332, 2017 | 58 | 2017 |
| Combination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer CM Goodwin, AM Waters, JE Klomp, S Javaid, KL Bryant, CA Stalnecker, ... Cancer research 83 (1), 141-157, 2023 | 43 | 2023 |
| Comparative proteomics of a model MCF10A-KRasG12V cell line reveals a distinct molecular signature of the KRasG12V cell surface X Ye, KC Chan, AM Waters, M Bess, A Harned, BR Wei, J Loncarek, ... Oncotarget 7 (52), 86948, 2016 | 26 | 2016 |
| Aberrant expression and subcellular localization of ECT2 drives colorectal cancer progression and growth DR Cook, M Kang, TD Martin, JA Galanko, GH Loeza, DG Trembath, ... Cancer research 82 (1), 90-104, 2022 | 24 | 2022 |
| KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018; 8: a031435 AM Waters, CJ Der | 21 | |
| CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment JE Klomp, YS Lee, CM Goodwin, B Papke, JA Klomp, AM Waters, ... Cell reports 37 (9), 2021 | 19 | 2021 |
| Targeting p130Cas-and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition AM Waters, TO Khatib, B Papke, CM Goodwin, GA Hobbs, JN Diehl, ... Cell reports 35 (13), 2021 | 19 | 2021 |
| Functional and biological heterogeneity of KRASQ61 mutations MV Huynh, GA Hobbs, A Schaefer, M Pierobon, LM Carey, JN Diehl, ... Science signaling 15 (746), eabn2694, 2022 | 18 | 2022 |
| Concurrent inhibition of ERK and farnesyltransferase suppresses the growth of HRAS mutant head and neck squamous cell carcinoma S Javaid, A Schaefer, CM Goodwin, VV Nguyen, FL Massey, M Pierobon, ... Molecular cancer therapeutics 21 (5), 762-774, 2022 | 12 | 2022 |
| Single Synonymous Mutations in KRAS Cause Transformed Phenotypes in NIH3T3 Cells AM Waters, R Bagni, F Portugal, JL Hartley PLoS One 11 (9), e0163272, 2016 | 12 | 2016 |
| TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors AC Edwards, CA Stalnecker, A Jean Morales, KE Taylor, JE Klomp, ... Cancer Research 83 (24), 4112-4129, 2023 | 11 | 2023 |
| Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy M Holderfield, BJ Lee, J Jiang, A Tomlinson, KJ Seamon, A Mira, ... Nature, 1-8, 2024 | 10 | 2024 |
| Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer KL Bryant, CA Stalnecker, D Zeitouni, JE Klomp, S Peng, AP Tikunov, ... Nature medicine 26 (6), 982-982, 2020 | 6 | 2020 |
| Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy M Singh, M Holderfield, B Lee, J Jiang, A Tomlinson, K Seamon, A Mira, ... | 4 | 2023 |
| Abstract LB-287: Combination therapies with CDK4/6 inhibitors to treat KRAS-mutant pancreatic cancer CM Goodwin, S Javaid, AM Waters, B Papke, R Yang, M Pierobon, ... Cancer Research 79 (13_Supplement), LB-287-LB-287, 2019 | 2 | 2019 |
